Skip to Content

Medifacts International Divests CRO Division

ROCKVILLE, Md., April 4, 2007 – Medifacts International, Inc. announces the successful the sale of its CRO division effective March 12, 2007 and is now operating as an independent provider of non-invasive cardiac safety and efficacy services (ABPM, Holter monitoring, ECG).


Michael Woehler, MEDIFACTS' President and Chief Executive Officer said: “The completion of the sale of the CRO division allows us to increase the focus on our primary business. We look forward to continuing to deliver the high-quality customer service and technology that our clients have become accustomed to and continuing the substantial growth we are experiencing in our Core Lab”.


Driven by best-in-class Science, Technology, and Quality Systems Management, Medifacts’ Core Lab has been undergoing very strong growth during the last year and the company is now established as one of the top 5 providers in this industry.


Our scientific expertise, proprietary WebHeart® technology, global presence and recognized quality leadership mean we are increasingly selected as the partner of choice by pharmaceutical and biotech drug developers.


We appreciate the continued support and loyalty from our Pharmaceutical & Biotech sponsors/partners as well as our colleagues in the clinical research services industry.


 More information about MEDIFACTS is available at






MEDIFACTS is a global leader providing quality Cardiac Safety and Efficacy services to pharmaceutical, biotech and medical device companies that are developing therapeutic drugs and products.


Medifacts International provides ECG, Holter, and ambulatory blood pressure monitoring services from offices in the US, Europe and Asia.  Medifacts International has been instrumental in shaping the industry by setting standards of quality and unsurpassed service.


Posted: April 2007